Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed)

archived

This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAIDs overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations which will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.

High